The Michael J. Fox Foundation is engaging with insurance companies and government health programs to discuss potential new Parkinson's disease therapies currently in clinical trials. The Foundation hopes these early conversations will influence coverage decisions for expensive new treatments like gene therapy and surgical interventions that could greatly improve patients' quality of life. At an October meeting, the Foundation shared patient perspectives and survey data on the impact of motor fluctuations with over 20 payers. They discussed three pipeline therapies that may help reduce "off" time within five years. The Foundation aims to proactively communicate with payers to increase the chances patients can access promising new treatments.